GNOM ETF

Keep a close eye on gene editing stocks as the market is projected to double in value by 2028, reaching approximately $10.6 billion compared to $5.3 billion in 2023, as reported by MarketsandMarkets.

GNMO invests across companies benefiting from advancements in the field of genomics within biotechnology. The fund's historical performance has been poor amid volatile stock prices for underlying holdings. Genomics may be the future, but still missing a blockbuster application to drive a wave of bullish momentum into the segment.

Gene editing could revolutionize how millions of patients are treated all over the world. That could create big opportunities for some of the most exciting gene-editing stocks.

Gene editing is revolutionizing medicine. For example, just weeks ago, the U.S. Federal Drug Administration approved a new gene-editing treatment for sickle cell disease and transfusion-dependent beta-thalassemia, a genetic disorder that prevents the production of hemoglobin in the blood and requires regular blood transfusions.